Abstract: The invention concerns specific pancreatic lipase inhibitors and their applications in the treatment and prevention of cardiovascular diseases, of lyperlipemia and of obesity, as well as diagnostic reagent and as regulating agent in a process of controlled lipolysis of triglycerides. Said inhibitors correspond in particular to a peptide consisting of a C-terminal fragment of pancreatic lipase including the recognition site of a colipase.
Type:
Grant
Filed:
September 27, 1999
Date of Patent:
August 13, 2002
Assignee:
Laboratoire Laphal (Laboratoire de Pharmacologie
Appliquee)